TECFIDERA

Type: Keyphrase
Name: TECFIDERA
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

NEW DATA FROM ENDORSE SHOW POSITIVE RESULTS CONTINUED OVER FIVE YEARS WITH TECFIDERA® (DIMETHYL FUMARATE)

CAMBRIDGE, Mass. – Sept. 11, 2014 – Today Biogen Idec (NASDAQ: BIIB) announced that five-year results from the ENDORSE Phase 3 extension study show TECFIDERA® (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living ... [Published MyNewsDesk - Sep 30 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

Multiple Sclerosis Drugs Could Transform Mar…

But things aren't done changing yet, as a September conference in Boston showed.At the meeting, held jointly by the American and European Committees for Treatment and Research in MS, the star presentation came from small biotech ReceptosMultiple-sclerosis ... [Published Investor's Business Daily - Sep 28 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Multiple Sclerosis Drugs Could Transform Market Again

Over the last four years, life for multiple-sclerosis patients has changed for the better as a new generation of powerful oral drugs has moved into a market dominated by injectables.But things aren't done changing yet, as a September conference in Boston ... [Published Investor's Business Daily - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 1 reports

Can Diet Affect Multiple Sclerosis?

Medscape Medical News By Sue Hughes More from WebMD FDA Panel Votes to Approve Gilenia, First Oral MS Drug New MS Drug Tecfidera: Q&A DNA... ... [Published KGet - Sep 25 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

Minding the gap in the UK multiple sclerosis market

Identifying brand opportunities in competitive markets with several new and innovative contenders requires a disciplined focus on the three pillars of brand success – experience, access and execution. Richard Goosey puts this into a UK perspective.The ... [Published pharmaphorum - Sep 25 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 2 reports

Biogen Idec Offers Growth Investors An Attractive Entry Point

By BMD Asset Management and Research :Biogen Idec BIIB reported strong second quarter earnings on July 23rd, causing analysts to revise their estimates considerably higher for both this year and next year. While the stock price has risen over 8% since ... [Published BioPortfolio - Sep 22 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Biogen Idec Announces Strides In Clinical Studies For MS Treatments

By Lori ClapperBiogen Idec announced clinical study results for three of its Multiple Sclerosis (MS) treatments at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee ... [Published Bioresearch Online - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Biogen Idec announces encouraging data from Phase III multiple sclerosis study

Biogen Idec, a biotechnology company, has announced that five-year data from the ENDORSE Phase III extension study show TECFIDERA provides sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis, or RRMS. Across ... [Published Individual.com - Sep 17 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 4 reports

Dimethyl fumarate (Tecfidera) follow on study

11 September 2014Author:Results from a five year follow on study show dimethyl fumarate remained effective over that period and there was no increased risk of side effects. People who started treatment when newly diagnosed showed most benefit. Reported ... [Published Multiple Sclerosis Trust - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 4 reports

Biogen's Phase 3 Tecfidera Trial Shows Positive 5-Year MS Data

Biogen Idec announced that five-year results from the ENDORSE Phase 3 extension study show Tecfidera (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis (RRMS). These ... [Published Drug Discovery and Development - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

ACTRIMS/ECTRIMS 2014 – Part 1

Update on oral therapies Gilenya Tecfidera Aubagio Drug vs. drug The annual congress of the European Committee on Treatment and Research in MS (ECTRIMS), held this year in conjunction with the Americas Committee (ACTRIMS), is the largest ... [Published MSology - Sep 11 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

NICE Recommends MS Drug Tecfidera

Biogen Idec said it will launch its multiple sclerosis drug Tecfidera within three months in England and Wales following a final coverage recommendation from the UK healthcare pricing watchdog.The National Institute for Health and Care Excellence recommended ... [Published FDA News - Sep 05 2014]

Quotes

The Leerink analysts seem to be indicating that the price issue is a bit more nuanced than previously assumed, however. Their conclusion: "[W]e continue to believe that a distinction should be drawn between the sticker shock and budget impact of orphan drugs."
"Many patients end up feeling so unwell after an injection, they have to inject on a Friday just to be ready for work on Monday" Receptos CEO Faheem Hasnain told IBD
That S1P mechanism is the same employed by Novartis " (NYSE: NVS ) Gilenya, which in 2010 was the first of the new oral drugs to hit the market. It represented a major advance not only because previous drugs had to be injected, but for safety reasons. Traditionally, MS has been treated with interferon-based drugs that can cause flu-like symptoms."
"The global multiple sclerosis market is estimated to grow by more than 50 per cent over five years"

More Content

All (129) | News (70) | Reports (1) | Blogs (57) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Orphan drugs may be pricey, but payers are bare... [Published FiercePharma - 15 hours ago]
The Complete Guide to Biotech ETFs [Published Yahoo! Finance - Sep 30 2014]
NEW DATA FROM ENDORSE SHOW POSITIVE RESULTS CON... [Published MyNewsDesk - Sep 30 2014]
Multiple Sclerosis Drugs Could Transform Mar… [Published Investor's Business Daily - Sep 28 2014]
Multiple Sclerosis Drugs Could Transform Market... [Published Investor's Business Daily - Sep 26 2014]
The 5 Best Biotech Stocks in 2014...so far [Published Motley Fool - Sep 26 2014]
Can Diet Affect Multiple Sclerosis? [Published KGet - Sep 25 2014]
Minding the gap in the UK multiple sclerosis ma... [Published pharmaphorum - Sep 25 2014]
Sovaldi sales suggest payer "tolerance" for drug [Published Insurance News Net - Sep 22 2014]
Merck KGaA declares $17B Sigma purchase 'quantu... [Published FiercePharma - Sep 22 2014]
Multiple Sclerosis Drug in Trials Reduces Relapse [Published EMax Health - Sep 22 2014]
Biogen Idec Offers Growth Investors An Attracti... [Published BioPortfolio - Sep 22 2014]
Biogen Idec Offers Growth Investors An Attracti... [Published Seeking Alpha - Sep 22 2014]
Why Biogen Stock Is Still An Investment Opportu... [Published Seeking Alpha - Sep 21 2014]
Biogen Idec Announces Strides In Clinical Studi... [Published Bioresearch Online - Sep 18 2014]
Biogen Idec and AbbVie report positive data fro... [Published Zenopa - Sep 17 2014]
Biogen Idec announces encouraging data from Pha... [Published Individual.com - Sep 17 2014]
AbbVie, Biogen to file MS drug next year [Published Medical Marketing And Media - Sep 16 2014]
Biogen/AbbVie Report Positive Data on MS Drug Z... [Published Yahoo! Finance - Sep 15 2014]
East Coast Biotech Roundup: Maraganore, Flex, N... [Published Xconomy - Sep 15 2014]
Making Treatment Decisions When There Is an Abu... [Published American Journal of Managed Care - Sep 14 2014]
The regulators got it wrong and throw drug away [Published Multiple Sclerosis Research - Sep 13 2014]
AbbVie and Biogen inch toward the FDA with once... [Published FierceBiotech - Sep 12 2014]
Dimethyl fumarate (Tecfidera) follow on study [Published Multiple Sclerosis Trust - Sep 12 2014]
Pair of Multiple Sclerosis Drugs Produces Posit... [Published Pharmacy Times - Sep 12 2014]
Biogen: Still Leading The Multiple Sclerosis Ma... [Published Bidness Etc - Sep 12 2014]
Why Biogen Idec Inc's Stock is Up 17% in 2014 [Published Motley Fool - Sep 12 2014]
Strong and sustained efficacy reported for Tecf... [Published Pharma Letter - Sep 12 2014]
Dive in: gaining leadership in a therapeutic area [Published PMLive - Sep 12 2014]
JobWatch: Big Biopharma Drives Bay State Growth [Published Genetic Engineering News - Sep 12 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The regulators got it wrong and throw drug away [Published Multiple Sclerosis Research - Sep 13 2014]
J Pakpoor et al. Is there an increased cancer risk in people with relapsing multiple sclerosis taking cladribine? MS J Suppl The FDA/EMA saw a few cancers in the Movecro (oral cladribine) trial called CLARITY led by ProfG and wanted further trials ...
How does tecfidera work [Published Multiple Sclerosis Research - Sep 12 2014]
Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Köhl J, Offermanns S, Wettschureck N, Schwaninger M.  Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.  J Clin Invest. 2014 1;124(5):2188-92. Taken orally, ...
New Data from ENDORSE Show Positive Results Con... [Published Business Wire Health News - Sep 11 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NEW DATA FROM ENDORSE SHOW POSITIVE RESULTS CONTINUED OVER FIVE YEARS WITH TECFIDERA® (DIMETHYL FUMARATE)IN A WIDE RANGE OF MULTIPLE SCLEROSIS PATIENTS ...
ACTRIMS/ECTRIMS 2014 – Part 1 [Published MSology - Sep 11 2014]
Update on oral therapies Gilenya Tecfidera Aubagio Drug vs. drug The annual congress of the European Committee on Treatment and Research in MS (ECTRIMS), held this year in conjunction with the Americas Committee (ACTRIMS), is the largest ...
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 27 2014]
Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence ( NICE ) has announced.  The NHS must now begin funding this treatment for eligible ...
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.